TR 391 Mouse Pathology Tables
INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)
TRIS (2-CHLOROETHYL) PHOSPHATE
NTP Experiment-Test: 05042-02 Report: PEIRPT05
Study Type: CHRONIC Date: 09/05/94
Route: GAVAGE Time: 16:28:52
Facility: Microbiological Associates
Chemical CAS #: 115-96-8
Lock Date: None
Cage Range: All
Reasons For Removal: All
Removal Date Range: All
Treatment Groups: Include All
a Number of animals examined microscopically at site and number of animals with lesion
Page 1
NTP Experiment-Test: 05042-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC TRIS (2-CHLOROETHYL) PHOSPHATE Date: 09/05/94
Route: GAVAGE Time: 16:28:52
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 175MG/KG 350MG/KG
FEMALE LOW FEM HIGHFEM
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 60 60 60
Scheduled Sacrifice 9 10 10
Early Deaths
Moribund 7 5 5
Dead 6 6 8
Gavage Death 5 2 2
Accident 1
Dosing Accident 1
Survivors
Terminal Sacrifice 31 37 35
Animals Examined Microscopically 50 50 50
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Gallbladder (41) (8) (43)
Histiocytic Sarcoma 1 (2%)
Intestine Large, Cecum (49) (10) (49)
Liver (50) (50) (50)
Hepatocellular Carcinoma 2 (4%) 2 (4%) 3 (6%)
Hepatocellular Adenoma 3 (6%) 2 (4%) 4 (8%)
Hepatocellular Adenoma, Multiple 1 (2%) 1 (2%)
Histiocytic Sarcoma 1 (2%)
Mesentery (7) (9) (9)
Fibrosarcoma, Metastatic, Skin 1 (11%)
Hemangiosarcoma, Metastatic, Skeletal Muscle 1 (11%)
Pancreas (49) (13) (48)
Fibrosarcoma, Metastatic, Skin 1 (8%)
Histiocytic Sarcoma 1 (2%)
Salivary Glands (50) (13) (48)
Mast Cell Tumor Malignant, Metastatic, Spleen 1 (8%)
Stomach, Forestomach (49) (49) (48)
Squamous Cell Papilloma 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (50) (13) (49)
____________________________________________________________________________________________________________________________________
Page 2
NTP Experiment-Test: 05042-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC TRIS (2-CHLOROETHYL) PHOSPHATE Date: 09/05/94
Route: GAVAGE Time: 16:28:52
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 175MG/KG 350MG/KG
FEMALE LOW FEM HIGHFEM
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Gland (49) (12) (50)
Adrenal Gland, Cortex (49) (12) (50)
Adrenal Gland, Medulla (49) (12) (48)
Pheochromocytoma Benign 1 (2%)
Pituitary Gland (48) (14) (44)
Pars Distalis, Adenoma 4 (8%) 3 (21%) 1 (2%)
Thyroid Gland (50) (12) (49)
Follicular Cell, Adenoma 1 (8%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Ovary (37) (16) (35)
Cystadenoma 1 (6%)
Uterus (50) (43) (50)
Deciduoma Benign 1 (2%)
Histiocytic Sarcoma 1 (2%)
Cervix, Hemangiosarcoma 1 (2%)
Endometrium, Adenocarcinoma 1 (2%)
Endometrium, Polyp Stromal 1 (2%) 3 (6%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (49) (13) (50)
Histiocytic Sarcoma 1 (2%)
Mast Cell Tumor Malignant 1 (2%)
Lymph Node (49) (17) (50)
Lymph Node, Mandibular (47) (12) (47)
Fibrosarcoma, Metastatic, Ear 1 (2%)
Mast Cell Tumor Malignant 1 (2%)
Lymph Node, Mesenteric (45) (16) (48)
Histiocytic Sarcoma 1 (2%) 1 (2%)
Mast Cell Tumor Malignant, Metastatic, Spleen 1 (6%)
Spleen (50) (20) (48)
Fibrosarcoma, Metastatic, Skin 1 (2%)
Hemangiosarcoma 1 (5%)
Histiocytic Sarcoma 1 (2%)
Mast Cell Tumor Malignant 1 (5%)
Thymus (45) (8) (40)
Mast Cell Tumor Malignant 1 (3%)
Page 3
NTP Experiment-Test: 05042-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC TRIS (2-CHLOROETHYL) PHOSPHATE Date: 09/05/94
Route: GAVAGE Time: 16:28:52
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 175MG/KG 350MG/KG
FEMALE LOW FEM HIGHFEM
____________________________________________________________________________________________________________________________________
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Mammary Gland (48) (33) (45)
Adenocarcinoma 3 (7%)
Fibroadenoma 1 (2%)
Skin (50) (48) (50)
Mast Cell Tumor Malignant, Metastatic, Spleen 1 (2%)
Trichoepithelioma 1 (2%)
Subcutaneous Tissue, Fibrosarcoma 1 (2%) 2 (4%)
Subcutaneous Tissue, Fibrosarcoma, Multiple 1 (2%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Skeletal Muscle (49) (14) (50)
Hemangiosarcoma 1 (7%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (50) (13) (49)
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (50) (50) (49)
Alveolar/Bronchiolar Adenoma 2 (4%) 2 (4%) 5 (10%)
Alveolar/Bronchiolar Carcinoma 1 (2%)
Fibrosarcoma, Metastatic, Skin 1 (2%) 1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver 2 (4%) 1 (2%)
Histiocytic Sarcoma 1 (2%) 1 (2%)
Squamous Cell Carcinoma, Metastatic, Ear 1 (2%) 1 (2%)
Nose (49) (14) (50)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Ear (2) (3)
Fibrosarcoma 1 (33%)
Squamous Cell Carcinoma 1 (33%)
External Ear, Squamous Cell Carcinoma 1 (50%)
Pinna, Fibrosarcoma 1 (33%)
Harderian Gland (49) (49) (49)
Adenoma 3 (6%) 6 (12%) 7 (14%)
Adenoma, Multiple 1 (2%)
Carcinoma 1 (2%)
Page 4
NTP Experiment-Test: 05042-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC TRIS (2-CHLOROETHYL) PHOSPHATE Date: 09/05/94
Route: GAVAGE Time: 16:28:52
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 175MG/KG 350MG/KG
FEMALE LOW FEM HIGHFEM
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM - cont
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (50) (49) (50)
Histiocytic Sarcoma 1 (2%)
Renal Tubule, Adenoma 1 (2%)
Urinary Bladder (49) (12) (49)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(50) *(50) *(50)
Histiocytic Sarcoma 1 (2%) 2 (4%)
Leukemia 1 (2%)
Lymphoma Malignant Lymphocytic 3 (6%) 2 (4%)
Lymphoma Malignant Mixed 7 (14%) 5 (10%) 3 (6%)
Mesothelioma Malignant 1 (2%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 5
NTP Experiment-Test: 05042-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC TRIS (2-CHLOROETHYL) PHOSPHATE Date: 09/05/94
Route: GAVAGE Time: 16:28:52
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 175MG/KG 350MG/KG
FEMALE LOW FEM HIGHFEM
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 25 26 37
Total Primary Neoplasms 29 37 45
Total Animals with Benign Neoplasms 14 16 19
Total Benign Neoplasms 14 21 23
Total Animals with Malignant Neoplasms 14 15 20
Total Malignant Neoplasms 15 16 22
Total Animals with Metastatic Neoplasms 3 3 4
Total Metastatic Neoplasm 3 6 6
Total Animals with Malignant Neoplasms
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant
Total Uncertain Neoplasms
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 6
NTP Experiment-Test: 05042-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC TRIS (2-CHLOROETHYL) PHOSPHATE Date: 09/05/94
Route: GAVAGE Time: 16:28:52
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 175MG/KG 350MG/KG
MALE LOW MALE HIGHMALE
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 60 60 60
Scheduled Sacrifice 8 10 8
Early Deaths
Moribund 10 8 12
Dead 14 13 9
Dosing Accident 1 1 2
Gavage Death 2 3 3
Survivors
Terminal Sacrifice 25 25 25
Missing 1
Animals Examined Microscopically 50 50 50
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Intestine Large, Cecum (47) (25) (46)
Intestine Large, Colon (49) (26) (47)
Intestine Small, Jejunum (45) (23) (44)
Adenocarcinoma 1 (4%) 2 (5%)
Liver (50) (50) (50)
Adenocarcinoma, Metastatic 1 (2%)
Adenocarcinoma, Metastatic, Intestine Small 1 (2%)
Fibrosarcoma, Metastatic, Skin 1 (2%)
Hemangiosarcoma 2 (4%) 4 (8%)
Hemangiosarcoma, Metastatic 1 (2%)
Hemangiosarcoma, Metastatic, Spleen 1 (2%)
Hepatoblastoma 1 (2%)
Hepatocellular Carcinoma 7 (14%) 10 (20%) 8 (16%)
Hepatocellular Carcinoma, Multiple 3 (6%) 2 (4%)
Hepatocellular Adenoma 12 (24%) 11 (22%) 11 (22%)
Hepatocellular Adenoma, Multiple 8 (16%) 7 (14%) 17 (34%)
Histiocytic Sarcoma 1 (2%)
Sarcoma, Metastatic, Spleen 1 (2%)
Mesentery (9) (2) (4)
Adenocarcinoma, Metastatic, Intestine Small 1 (25%)
Fibrosarcoma, Metastatic, Skin 1 (25%)
Lipoma 1 (11%)
Pancreas (49) (26) (49)
Fibrosarcoma, Metastatic, Skin 1 (2%)
Salivary Glands (49) (24) (49)
Stomach, Forestomach (49) (50) (49)
Squamous Cell Papilloma 1 (2%) 1 (2%)
Glandular, Mast Cell Tumor Malignant,
Page 7
NTP Experiment-Test: 05042-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC TRIS (2-CHLOROETHYL) PHOSPHATE Date: 09/05/94
Route: GAVAGE Time: 16:28:52
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 175MG/KG 350MG/KG
MALE LOW MALE HIGHMALE
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM - cont
Metastatic, Skin 1 (2%)
Stomach, Glandular (50) (47) (47)
Adenocarcinoma, Metastatic 1 (2%)
Adenocarcinoma, Metastatic, Intestine Small 1 (2%)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (50) (25) (50)
Carcinoma, Metastatic, Uncertain Primary Site 1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver 1 (4%)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Gland, Cortex (48) (23) (48)
Adrenal Gland, Medulla (46) (23) (43)
Pheochromocytoma Malignant 1 (2%)
Pheochromocytoma Benign 1 (2%)
Islets, Pancreatic (49) (25) (49)
Adenoma 1 (2%)
Mast Cell Tumor Malignant, Metastatic, Skin 1 (2%)
Thyroid Gland (49) (23) (49)
Follicular Cell, Adenoma 1 (2%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Epididymis (49) (24) (47)
Preputial Gland (7) (3) (5)
Carcinoma 1 (33%)
Seminal Vesicle (48) (26) (50)
Testes (50) (24) (50)
Interstitial Cell, Adenoma 2 (4%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (50) (25) (49)
Hemangiosarcoma, Metastatic 2 (4%)
Hemangiosarcoma, Metastatic, Spleen 1 (2%) 1 (4%)
Mast Cell Tumor Malignant, Metastatic, Skin 1 (2%)
Page 8
NTP Experiment-Test: 05042-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC TRIS (2-CHLOROETHYL) PHOSPHATE Date: 09/05/94
Route: GAVAGE Time: 16:28:52
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 175MG/KG 350MG/KG
MALE LOW MALE HIGHMALE
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM - cont
Lymph Node (50) (27) (49)
Lymph Node, Mandibular (46) (22) (44)
Mast Cell Tumor Malignant, Metastatic, Skin 1 (2%)
Lymph Node, Mesenteric (48) (24) (44)
Histiocytic Sarcoma 1 (2%)
Spleen (50) (28) (49)
Hemangioma 1 (4%)
Hemangiosarcoma 3 (6%)
Hemangiosarcoma, Multiple 1 (4%)
Histiocytic Sarcoma 1 (2%)
Mast Cell Tumor Malignant, Metastatic, Skin 1 (2%)
Sarcoma 1 (2%)
Thymus (29) (17) (33)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Skin (50) (35) (49)
Hemangiosarcoma, Metastatic, Spleen 1 (3%)
Mast Cell Tumor Malignant 1 (2%)
Subcutaneous Tissue, Fibroma 3 (9%)
Subcutaneous Tissue, Fibroma, Multiple 1 (2%)
Subcutaneous Tissue, Fibrosarcoma 1 (2%) 4 (11%) 2 (4%)
Subcutaneous Tissue, Fibrosarcoma, Multiple 1 (2%)
Subcutaneous Tissue, Hemangiosarcoma 1 (3%)
Subcutaneous Tissue, Sarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
None
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (50) (25) (50)
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (50) (50) (50)
Alveolar/Bronchiolar Adenoma 7 (14%) 9 (18%) 7 (14%)
Alveolar/Bronchiolar Adenoma, Multiple 2 (4%) 2 (4%)
Alveolar/Bronchiolar Carcinoma 3 (6%) 1 (2%) 2 (4%)
Carcinoma, Metastatic, Uncertain Primary Site 1 (2%)
Fibrosarcoma, Metastatic, Skin 1 (2%) 1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver 2 (4%) 3 (6%) 2 (4%)
Page 9
NTP Experiment-Test: 05042-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC TRIS (2-CHLOROETHYL) PHOSPHATE Date: 09/05/94
Route: GAVAGE Time: 16:28:52
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 175MG/KG 350MG/KG
MALE LOW MALE HIGHMALE
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM - cont
Histiocytic Sarcoma 1 (2%)
Mast Cell Tumor Malignant, Metastatic, Skin 1 (2%)
Nose (50) (25) (50)
Carcinoma, Metastatic, Harderian Gland 1 (2%)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Eye (6) (5) (7)
Mast Cell Tumor Malignant, Metastatic, Skin 1 (14%)
Harderian Gland (48) (49) (47)
Adenoma 5 (10%) 8 (16%) 3 (6%)
Adenoma, Mild 1 (2%)
Adenoma, Multiple 1 (2%)
Carcinoma 1 (2%)
Bilateral, Adenoma 1 (2%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (50) (50) (50)
Carcinoma, Metastatic, Uncertain Primary Site 1 (2%)
Hemangiosarcoma 1 (2%)
Hepatocellular Carcinoma, Metastatic 1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver 1 (2%)
Mast Cell Tumor Malignant, Metastatic, Skin 1 (2%)
Renal Tubule, Adenoma 1 (2%) 1 (2%)
Renal Tubule, Carcinoma 1 (2%)
Urinary Bladder (50) (24) (49)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(50) *(50) *(50)
Histiocytic Sarcoma 1 (2%)
Lymphoma Malignant Mixed 2 (4%) 3 (6%) 1 (2%)
Lymphoma Malignant Undifferentiated Cell 2 (4%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 10
NTP Experiment-Test: 05042-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC TRIS (2-CHLOROETHYL) PHOSPHATE Date: 09/05/94
Route: GAVAGE Time: 16:28:52
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 175MG/KG 350MG/KG
MALE LOW MALE HIGHMALE
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 38 39 42
Total Primary Neoplasms 64 68 71
Total Animals with Benign Neoplasms 28 28 32
Total Benign Neoplasms 37 42 48
Total Animals with Malignant Neoplasms 22 21 21
Total Malignant Neoplasms 27 26 23
Total Animals with Metastatic Neoplasms 6 5 6
Total Metastatic Neoplasm 11 9 20
Total Animals with Malignant Neoplasms 1
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant
Total Uncertain Neoplasms
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 11
------------------------------------------------------------
---------- END OF REPORT ----------
------------------------------------------------------------
--multipart-boundary
Content-type: text/plain
Range: bytes 66330-66330/66330
--multipart-boundary--